²Ä¤E³¹¡GªvÀø¤Î¹w¨¾
«e¨¥
¤j³¡¤À±w¦³Â²³æ¤HÃþ¬y·Pªº¯f¤H¡A¯S§O¬O«C¤Ö¦~¤Î¦~»´ªº¦¨¤H¡A¯à°÷®Ú¾Ú¯f¯g±µ¨üªvÀø¡A¦ÓµL»Ý¯S©wªº¤¶¤J¡CµM¦Ó¡A¹ï©ó¦~ªøªº¤H¡A¥Î§Ü¯f¬rÃĪ«ªvÀø¬O¤@Ó¦nªº¿ï¾Ü¡C¹ï©óÓ§O°ª¦Mªº¤H¡A¯S§O¬O¦³¼ç¦bÂåÀøª¬ªp¡A¥H¤Î¦b¤@¨Ç¯S§O±¡§Î¤Uªº¯f¤H¡A§óÀ³¦Ò¼{³o¨ÇÃĪ«¡C
¯«¸gÓi»ÄžJ§í¨î¾¯¡A¹ï©ó©Ò¦³¦b¤HÃþ¤Þ°_¯e¯fªºÅÜÅé¡A¥]¬A1918¦~²±¦æªº¯f¬r¡A¬O¦³®Äªº
(Tumpey
2005)¡C¦b¤HÃþH5N1¬y·P¡A¥H¤fªAªº¯«¸gÓi»ÄžJ§í¨î¾¯¶ø¥q¥Lºû (oseltamivir)
ªvÀø¡A¦b¤@¨Ç¹ê¨Ò¤¤¦ü¥G¦³®Ä¡A¦ý¦b¨ä¥Lªº«h¦³¥i¯à¥¢±Ñ¡C³Ìªñ¡A´N«ü¥X¦³@ÃĪº«~ºØ¥X²{ (de
Jong 2005)¡C¦¹¥~¡A¦bÄY«ªºH5N1Ӯפ¤¡AªvÀøªº¾¯¶q¤Î«ùÄò®É¶¡¬Ý¨Ó¤]¤£¦P¡C
¦pªG±N¨Óµo¥Í¥þ²y©Ê¤j³W¼Òªº¬Ì¯g¡A¦b¨S¦³¹ï§Ü·s«~ºØªº¬Ì]©Î¬Ì]µu¯Êªº¦´Á¡A§Ü¯f¬rÃĪ«©Î·|¾á·í¤@Ó«nªº¨¤¦â¡C
§Ü¯f¬rÃĪ«
²{¦b¯àªvÀø¥Ò«¬¬y·P·P¬Vªº¥|ºØ§Ü¯f¬rÃĪ« (¨âºØ¯«¸gÓi»ÄžJ§í¨î¾¯¤Î¨âºØM2Â÷¤l³q¹D§í¨î¾¯)
¤¤¡A¥u¦³¯«¸gÓi»ÄžJ§í¨î¾¯¶ø¥q¥Lºû¤Î¤ã¨º¦Ì°¶ (zanamivir) ¯à¦P®É¹ï¤A«¬¬y·P¦³®Ä¡CY¦b¯gª¬¶}©l¥X²{«á´X¤p®É¤º¡A©Ò¥ÎÃĪ«¬O·|³Ì¦³®Äªº¡A¦ÓÃĪ«´¶¹MÀò³\¥i¦bªì´Á¯f¯g¥X²{ªº48¤p®É¤ºªA¥Î¡A¡C¥¦Ì¯à´î»´¯e¯fªºÄY«µ{«×¡A¥H¤Î°§C¬y·P¯gª¬ªº±j¯Pµ{«×¡A´î¤Ö¯e¯fªº«ùÄò®É¶¡¤@¦Ü¤T¤é¡C¦ý¬O¡A§Ü¯f¬rÀøªk¯à´î¤ÖÄY«¨Öµo¯g¤Î¦í°|ªºµ{«×¤´¦bª§½×¤¤¡CªvÀøªº¦¨¥\¡A¬Yµ{«×¤W¨ú¨M©ó¥X²{¯gª¬¤Î¶}©l§Ü¯f¬rªvÀø¶¡®É¶¡¤WªºÅܼơG¦b¯gª¬¥X²{«á¶V¦¶}©lªvÀø¶V¦n¡C
¯«¸gÓi»ÄžJ§í¨î¾¯¶ø¥q¥Lºû¤Î¤ã¨º¦Ì°¶¡A¬Û¹ïM2Â÷¤l³q¹D§í¨î¾¯ª÷è¤AÓi(rimantadine)
¤Îª÷èÖJÓi(amantadine)¡A¦³¸û¤Öªº°Æ§@¥Î¡A¦Ó@Ãĩʪºµo¥ÍÀW²v¤]¸û§C¡C³o¨ÇÃĪ«ªºÁ{§ÉÃIJz¾Ç¡A°Æ§@¥Î¤Î@ÃÄ·§ªp¦b
(ÃĪ«)
¤@³¹¤¤¦³¸û¸Ô²Óªº°Q½×¡C
¯«¸gÓi»ÄžJ§í¨î¾¯ ¶ø¥q¥Lºû (¯S±ÓºÖ®)¡A¬O²{¦bªvÀø¤HÃþH5N1¬y·PªºÃĪ«³Ì¨Î¿ï¾Ü¡C
¯«¸gÓi»ÄžJ§í¨î¾¯
³o¨ÇÃĪ«¡A¦b1999¤Î2000¦~¤Þ¤J¡A¥H¼Ò¥é¯«¸gÓi»ÄžJªº¤ÑµM°ò½è
¡Ð ³è²G»Ä¡A§«Ãª¬y·P¯«¸gÓi»ÄžJªº¥¿±`§@¥Î (Varghese
1992, Varghese
1995)¡C¯f¬r¯«¸gÓi»ÄžJ¬Ot³d¤À¶}·s§Î¦¨ªº¯f¬r²É¤l¤Wªº³è²G»Ä´Ý°ò¡A¦b¥¦ÌªºÄÀ©ñ§êºt«nªº¨¤¦â¡A¥H¤Î«P¶i©I§l¹D¤ºªº¯f¬rÂX´²¡C·í¬y·P¯f¬r²É¤l¼ÉÅS©ó¯«¸gÓi»ÄžJ§í¨î¾¯¡A¥¦Ì·|¦b±J¥D²ÓMªí±»E¶°¡A§½¤FÂH½¤¤À¯µª«¶¡ªº·P¬Vµ{«×
(McNicholl
2001) ¤Î°§C¯f¬r·P¬V¤O (©ó http://content.nejm.org/cgi/content/full/353/13/1363/F1
¨£¹Ï)¡C¹êÅçÃÒ¾Ú¶i¤@¨B´£¥X¬y·P¯«¸gÓi»ÄžJ¥i¯à¹ï¤HÃþ®ðºÞÅÖ¤ò¤W¥Öªºªì´Á¯f¬r¤J«I¬O¥²nªº (Matrosovich
2004)¡C¯«¸gÓi»ÄžJ§í¨î¾¯ªº³]p¬O³q¹L¤ÀªR¬y·P¯«¸gÓi»ÄžJªº¤Tºûµ²ºc¡A±q¦Ó³zÅS¨ä¶Ê¤Æ³¡¦ìªº¦ì¸m¤Îµ²ºcªºµ²ªG
(Colman
1983)¡C
³\¦h°·±d¦¨¤HªºªvÀø¬ã¨sÅã¥Ü¡A¦bªì´Á¯f¯g¥X²{«á36¦Ü48¤p®É¤ºªA¥Î¯«¸gÓi»ÄžJ§í¨î¾¯¡A¯à´î¤Ö¦³¯gª¬ªº¯e¯f´Á¤@¦Ü¨â¤Ñ
(Hayden
1997, Monto
1999, Treanor
2000, Nicholson
2000, Hedrick
2000, Cooper
2003, Whitley
2001, Aoki
2003)¡C¦´Á¹ê¬IªvÀø¹ïªvÀø¥\®Ä¬O¨M©w©Êªº (Aoki
2003, Kawai
2005)¡C¦bµo¿N«á12¤p®É¤º¶}©lªA¥Î¯«¸gÓi»ÄžJ§í¨î¾¯¡A¬Û¹ï©ó¦b48¤p®É«á¤~ªA¥Î¡A¯à°÷ÁYµu¯e¯f¶W¹L¤T¤é¡Cµo¿Nªº«ùÄò®É¶¡¡A¯f¯gªºÄY«©Ê¡A¥H¤Î¦^´_¥¿±`¬¡°Êªº®É¶¡¤]»P§Ü¯f¬r¤¶¤Jªº¹ê¬I®É¶¡¦³Ãö¡C
¤@¶µ¥[®³¤jªø´Á¬ÝÅ@³]¬Iªº¬ã¨sÅã¥Ü¡A¦b¯gª¬¥X²{«á48¤p®É¤º¥H
¶ø¥q¥Lºû ªvÀøªº¦~¬ö¸û¤jªºÀø¾i°|©w©~ªÌ¡A¸û¤Ö¾÷·|¶}µ¹§Ü¥Í¯À¡A°e°|¡A©Î¦º¤` (Bowles
2002)¡C°Æ§@¥Î¸û¨u¨£ (4.1%)¡A³Ì±`¨£ªº¦³¸¡Âm (1.6%)¡A«y¹Â (0.7%)¡A²V¶Ã
(0.5%) ¤Îäú¤ß (0.5%)¡C¥t¤@¶µ¬ã¨s«ü¥X¬y·Pªº¶ø¥q¥LºûªvÀøªk¯à´î¤Ö¤U©I§l¹D¨Öµo¯g¡A§Ü¥Í¯Àªº¨Ï¥Î¡A¥H¤Î°·±d©M
[°ª¦M] ¦¨¤Hªº¦í°| (Kaiser
2003)¡C
¹w¨¾¸ÕÅç«ü¥X¡A¦b¬y·P¶}©lÃzµo®É¡A¹w¨¾©Ê¦aµ¹¤©¯«¸gÓi»ÄžJ§í¨î¾¯¯à°§C¬y·P²£¥Íªº·ÀI60-90%
(Monto
1999b, Cooper
2003)¡C·í¹w¨¾©Ê¦aµ¹¤©¦³¬y·P¸ñ¶HӮתº®a®x±µÄ²®É¡A¹ï§ÜÁ{§É¬y·Pªº¨¾Å@¥\®Ä´¶¹M¤j©ó80%
(Hayden
2000, Kaiser
2000, Welliver
2001, Monto
2002)¡C
¤H̹ﯫ¸gÓi»ÄžJ§í¨î¾¯´¶¹M¦³¦nªº@¤O¡Cµu¼Èªº¸zG¤£¦w (äú¤ß¡A¹Ã¦R)
¬O¶ø¥q¥Lºû¥Dnªº°Æ§@¥Î¡C¯S§Oª`·Nªº¬O¡A¶ø¥q¥Lºû¤Î¤ã¨º¦Ì°¶¥iÆ[¹î¨ìªº¦w¥þ·§ªp»PM2§í¨î¾¯ª÷è¤AÓi¤Îª÷èÖJÓi,ªº¬Û¤ñ¬O¦³§Qªº(Freund
1999, Doucette
2001)¡C
«Ü¤Ö±¡ªp¤U¡A¨Ï¥Î¶ø¥q¥Lºû®É©Î·|²£¥ÍÄY«ªº¥Ö½§/¹L±Ó¤ÏÀ³¡A¦]¦¹¯f¤HÀ³ª`·N¡AY¥X²{ÄY«ªº¯l©Î±Ó·P¯gª¬¡AÀ³°±¤îªA¥Î¶ø¥q¥Lºû¨Ã»P¨ä«O°·´£¨ÑªÌÁpµ¸
(FDA 2005)¡C¦Ü©ó¤ã¨º¦Ì°¶¡A¦b¦³¼ç¦bªÍª¬ºAªº¯f¤H¡A¦pý³Ý©ÎºC©Êªý¶ë©ÊªÍ¯f¡A¤w³ø§i«ü¥X·|µo¥Í¤ä®ðºÞµjÅˤΪͥ\¯à°I°h
(²Ä1¬í¥Î¤O©I®ð¶q (FEV1) ©Î©I®ð®p¬y¶q)¡C¦]¦¹¤ã¨º¦Ì°¶´¶¹M¤£³Q«ØÄ³¥Î§@ªvÀø¾Ö¦³¼ç¦b®ðºÞ¯e¯fªº¯f¤H¡A¦Ó¥B¥çÀ³¦b¥X²{¤ä®ðºÞµjÅ˩Φ³ªÍ¥\¯à°I°hªº¯f¤H¨¤W¤¤¤î¨Ï¥Î
(Relenza
2003)¡C
ÃĪ«»PÃĪ«¤§¶¡¤¬¬Û¼vÅTªº¥i¯à©Ê¡A¦b¶ø¥q¥Lºû¤Î¤ã¨º¦Ì°¶¨â¤è³£«Ü§C¡C¦b¶ø¥q¥Lºû¡A©Î·|µo¥ÍµÇ¤pºÞ¤W¥Ö²ÓMtÂ÷¤lÂà¹B³J¥Õ¤Þ°_ªºÄvª§©Ê¤Àªc§í¨î¡C¤þÁDµÎ©Î·|¶W¹LÂù¿ßn¤Æ¶ø¥q¥Lºûªº¨t²Î±µÄ²
(Hill 2002)¡C
¹ï¯«¸gÓi»ÄžJ§í¨î¾¯¦³§ÜÃĩʪº¤ÑµM¦s¦bªº¤HÃþ¥Ò«¬¬y·P¯f¬r«~ºØ¬Û«H¬O¤£¦s¦bªº
(McKimm-Breschkin
2003)¡C¦bÅé¥~¡ANA¬ðÅÜ E119V¡BR292K¡BH274Y¤ÎR152K»P¶ø¥q¥Lºûªº§ÜÃĩʦ³Ãö
(McKimm-Breschkin
2003)¡C¤@¨Ç¬ðÅÜ¡A¦pR292K¤ÎH274Y¬ðÅÜ¡A·|¾ÉP¥\¯à¤W¦³¯Ê³´¥H¤Î§´¨ó¯f¬r¾A©ÊªºžJ¡C¦Ó¥B¤]«ü¥X¤F±a¦³³o¨Ç¬ðÅܪº¯f¬r¤£¤Ó¥i¯à¦b¤HÃþ²£¥Í«¤jªºÁ{§É«áªG
(Tai
1998, Carr 2002, Ives 2002, Herlocher 2004)¡CµM¦Ó¡A³Ìªñ¤@¥÷³ø§i´yz¤F¤@°¦±a¦³H274Y¬ðÅܪº§ÜÃÄ©ÊH5N1«~ºØ¡A¦b¨â¦W¯f¤H¤¤¤ÞP¯f¬r¦å¯g¡A¦Ó¥L̳̫á¦]¸V¬y·P¦Ó¦º¤`
(de
Jong 2005)¡C¤ã¨º¦Ì°¶¦ü¥G«O¯d¤FÅé¥~¬¡©Ê¦Ó¥i¹ï§Ü¤@¨Ç§Ü¶ø¥q¥Lºûªº«~ºØ (McKimm-Breschkin
2003,
Mishin 2005)¡C
¸gÁ{§É¨Ï¥Î«á¡A¦b¦¨¤H¤Î¤j©ó13·³ªº«C¤Ö¦~¤¤§ÜÃÄ«~ºØªºµo¥Í²v¤ñ¨àµ£¬°§C¡C¤@¶µ¬ã¨s¦b9/50ÓªA¥Î¶ø¥q¥Lºûªº¨àµ£
(18%) ¤¤µo²{¯«¸gÓi»ÄžJ¬ðÅÜ (Kiso 2004)¡C³o¨Çµo²{¬OȱoÃöª`ªº¡A¦]¬°¨àµ£¬O¬y·P¯f¬r¦bªÀ°Ïªº¤@Ó«n¶Ç¼½´C¤¶¡C¦bH5N1²±¦æÓ®×¤¤¡AH5N1¨à¬ì¯f¤Hªº¶ø¥q¥LºûªvÀø¤¤¥X²{§ÜÃĩʪºÀW²v¨Ã¤£©ú½T¡A¦ý«Ü¥i¯à¤£§C©ó±q·P¬V²{¦b¬y¦æªº¤HÃþ¬y·P¯f¬rªº¨àµ£¤¤©ÒÆ[¹î±o¨ìªº
(Hayden 2005)¡C
¯«¸gÓi»ÄžJ§í¨î¾¯¹ï¤Þ°_1918¦~¬y¦æ¯fªº¯f¬r¬O¦³®Äªº (Tumpey
2002)¡C
±Ä¥Î¯«¸gÓi»ÄžJ§í¨î¾¯ªº¼x¥ü
¶ø¥q¥Lºû (¯S±ÓºÖ®) ¤Î¤ã¨º¦Ì°¶
(¼Ö·P²M®) ¬O²{¦b³\¥i¥Î§@¥Ò«¬¤Î¤A«¬¬y·PªºªvÀøªº¡C¥u¦³¯f¯g¦bªì´Áªº48¤p®É¤º¥X²{¤~À³¨Ï¥Î¡A¦Ó¥B²z·Q¦aÀ³¦b¯e¯fµo¥Í12¤p®É¤º¹ê¬I¡C
¥t¥~¡A¶ø¥q¥Lºû¡A¦ý«D¤ã¨º¦Ì°¶ (°£¨âÓ°ê®a¥~)¡A·í¦b48¤p®É¤º¼ÉÅS©ó¬y·P¤Î¬y·P¦bªÀ°Ï¤¤¬y¦æ®É¡A¥ç³\¥i¥Î§@¹w¨¾ªvÀø;
¥¦¥ç³\¥i¥Î§@¯S®íªº±¡ªp (¨Ò¦p·í±µºØ¬Ì]¤£¯àÂл\¶Ç¬V¤¤ªº«~ºØ) ¨Ó¨¾¤î¬y·P²±¦æ¡C
¶ø¥q¥Lºû¤Î¤ã¨º¦Ì°¶¦ü¥G¦³®t¤£¦hªº¥\®Ä¡A¦ý¬O¥¦Ì¦b¨ä¶Ç°e¼Ò¦¡¤Î®e§Ôµ{«×¦³©Ò¤£¦P¡C¤ã¨º¦Ì°¶¬O¥H§l¤Jªº§Î¦¡¨Ó¶Ç°e¨Ã¥B¬Û·í®e©ö¦a³Q®e§Ô;
µM¦Ó¡A¦b¤pµ£¡A¯S§O¦~¬ö¬O¤p©ó8·³ªº¡A³q±`¤£¯à¦³®Ä¦a¹B¥Î¶Ç°e¨t²Î¡A¦ÓªøªÌ¥ç³£¥i¯à¦³§xÃø (Diggory
2001)¡C¶ø¥q¥Lºû¬O¥HÃĤYªº§Î¦¡ªA¥Î¡A¦ý¥i¯à¦b¤@¨Ç¯f¤H¤¤¥i¯à²£¥Íäú¤ß¤Î¹Ã¦R¡C
M2Â÷¤l³q¹D§í¨î¾¯
ª÷èÖJÓi¤Îª÷è¤AÓi¬O¤TÀô¹ïºÙª÷èÖJÓi¡C¦b1960¦~¥Nµo²{¥¦Ì¯à§í¨î¬y·P«~ºØ(Stephenson
2001)¡C¥¦Ì¥u¹ï¥Ò«¬¬y·P¯f¬r¦³®Ä (¤A«¬¬y·P¨S¦³M2³J¥Õ)¡A¸û¯«¸gÓi»ÄžJ§í¨î¾¯¦³§ó¦hªº°Æ§@¥Î¡A¥H¤Î¥i¯à¿ï¾Ü¯à§Ö³t¶Ç¼½ªº§ÜÃĩʯf¬r¡C
M2§í¨î¾¯ªý¶ë¥Ñ¾î¸ó¯f¬r½¤ªºM2³J¥Õ§Î¦¨ªº¡A¥H¤Î¯f¬r²æ´ß©Ò»Ý
(¸Ô±¡½Ð¬Ý [ÃĪ«]
¤@³¹) ªºÂ÷¤l³q¹D (Hay
1985, Sugrue 1991)¡CY¦b¯e¯fµo¥Í24¤p®É¤º¶}©lªA¥Î¡A¨âºØÃĪ«§@¬°ªvÀø³£¬O¦³®Äªº¡A¯à´î¤Öµo¿N¤Î¨ä¥L¯f¯g¤@¦Ü¨â¤Ñ
(Wingfield 1969, Smorodintsev 1970, van Voris
1981)¡C
¦b¬y·P¬¡ÅD®É´Á¨C¤Ñ¹w¨¾ªvÀø¯à°§C·P¬V²v 50-90% (Dawkins
1968, Dolin 1982, Clover 1986)¡CµM¦Ó®a®x¦b¼ÉÅS«áªº¹w¨¾¦ü¥G¬O¦³°ÝÃDªº¡C¦b¤@¶µ¬ã¨s¤¤¡Aª÷è¤AÓi¦b«OÅ@®a®x¦¨û§K¨ü¥Ò«¬¬y·P·P¬V¤¤¨Ã¨S¦³®Ä
(Hayden 1989)¡C
¸zG¯gª¬¬OÃö«Y¨ìª÷èÖJÓi¤Îª÷è¤AÓiªº¥Dn°Æ§@¥Î¡C¥[¤W¡Aª÷èÖJÓi¦³¼sªx½d³òªº¬r©Ê¡A¦Ó³o©Î³\¬OÃĪ«¤ÏÁxÆP§@¥Îªº¤@³¡¤Àì¦]¡C¥t¥~¡A¬Û·í©ó¤T¤À¤§¤@ªº¯f¤H¦b¤¤éªvÀø´Á¶¡©Î·|¥X²{¦¸nªº¥i°f¤¤¼Ï¯«¸g¨t²Î°Æ§@¥Î
(van Voris 1981)¡C·íÃĪ«¦b¦~»´°·±dªº§ÓÄ@ªÌ¤W´ú¸Õ¶W¹L¥|¬P´Á®É¡Aµo²{¬Û¦Pªº°Æ§@¥ÎÀW²v¡C¦b44¤H·í¤¤¡A¤j³¡¤À¤H³£¾A·í¦a§Ô¨ü¨ì°Æ§@¥Î
(ÀY·w¡BµJļ¤Î¥¢¯v)¡A¦ý6¦W§ÓÄ@ªÌ¦]ÅãµÛªº«è¨¥¦Ó¤¤¤î¤F¨Ï¥Îª÷èÖJÓi¡C¦b¹L¥b¼ÆÄ~Äò¨Ï¥Îª÷èÖJÓiªº¤H¤¤°Æ§@¥Î²×¤î¡C16¦W§ÓÄ@ªÌ¦b»Ýn«ùÄòª`·Nªº¤u§@¤¤ªºªí²{ÅÜ®t
(Bryson 1980)¡C¦b¬ã¨s¥Ò«¬¬y·PÃzµo´Á¶¡ªº450¦W§ÓÄ@ªÌ®É¡Aª÷è¤AÓi¤Îª÷èÖJÓiªº¹w¨¾§@¥Î¥i¥H¤ñ±o¤W¡C14%ª÷è¤AÓi¤Î9%ª÷èÖJÓiªº²Õ§O¥X²{¬y·Pª¬¯e¯f
(Dolin 1982)¡C°ò©ó¤¤¼Ï¯«¸g¨t²Î°Æ§@¥Î¦Ó°h¥Xªº¤H¡A¬Û¹ï©ó¦bª÷è¤AÓi¥X²{¸û¤Ö(6%)¡A¦Ó¦bª÷èÖJÓi«h¸û¦h(13%)¡C
M°ò¦]ªºÂI¬ðÅÜ·|¤ÞPM2³J¥Õ¸ó½¤³¡¤ÀªºÓi°ò»Ä§ïÅÜ¡A¥H¤Î¥i¯àµ¹¤©°ª«×¹ïª÷èÖJÓiªº§ÜÃĩʡC³o§ÜÃĩʪº¿ò¶Ç·Ç«h¬Ý¨Ó¦ü¥G¬OM2Â÷¤l³q¹D¸ó½¤³¡¤À¦ì¸m26¡A27¡A30¡A31©Î34ªº³æÓi°ò»ÄÅܲ§
(Hay
1985)¡C³o¨Ç¬ðÅÜÅé¦p³¥¥Íªº¯f¬r¯ë±a¦³¬r©Ê¤Î¥i¶Ç¼½ªº¡C¦b¤@¸V³¾«~ºØ¡A¦b³q¹L³¶³¾6¦¸¡A¶W¹L20¤éªº®É´Á«á¡A¥¦Ì¥ç¦b°ò¦]¤Wéw¡A¨S¦³¥X²{¦^´_¨ì³¥¥Í«¬ªº±¡ªp
(Bean 1989)¡C¨º¨Ç«~ºØ¥i¯à·|¦b³Ì¦h¤T¤À¤§¤@±Â¨üª÷èÖJÓi©Îª÷è¤AÓiªvÀøªº¯f¤H¤¤¥X²{¡F¦b§K¬Ì¤O¤£¨¬ªº¤H¤¤³oӦʤÀ²v©Î·|§ó°ª
(Englund
1998)¡C§ÜÃĩʥҫ¬¬y·P¯f¬r (H3N2) ¥i¥H±q¨Ï¥Îª÷è¤AÓiªvÀøªº¤pµ£¤Î¦¨¤H¦b±µ¨üªvÀø¥u»Ý¨â¤Ñ«á«K¥Í²£
(Hayden
1991)¡C¤@¨Ç»PªF«n¨È¤HÃþ¯e¯f¦³ÃöªºH5N1«~ºØ¡A¹ïª÷èÖJÓi¤Îª÷è¤AÓi¬O¦³§ÜÃĩʪº¡@(Peiris¡@2004,
Le
2005)¡A¦Ó²±¦æ©ó¦L¥§¡A¥H¤Î³Ìªñ¤¤°ê¡B»X¥j¡B«Xù´µ¡B¤g¦Õ¨ä¡Bù°¨¥§¨Èªº«~ºØªº¹jÂ÷ª«¡A³£¹ïª÷èÖJÓi±Ó·P
(Hayden
2005)¡C
ªñ´Á¡Aª÷èÖJÓiÅܱo¨ü¨ì¤@©wªºÀ£¤O¡A¦]¬°µo²{¤F91%¹jÂ÷¦Û¬ü°ê²{®É¬y·P©uªº¯f¤Hªº¥Ò«¬¬y·PH3N2¯f¬r¡A¦bM2³J¥Õ¦ì¸m31§t¦³¤@ÓÓi°ò»Ä§ïÅÜ¡A¥HPª÷èÖJÓi¤Îª÷è¤AÓiªº§ÜÃĩʡC°ò©ó³o¨Çµ²ªG¡A¯e¯f¹w¨¾¤Î±±¨î¤¤¤ß«ØÄ³¡A¦b2005-06¾l¤Uªº¬y·P©u¡A³£¤£n¦b¬ü°ê¨Ï¥Îª÷èÖJÓi¤Îª÷è¤AÓi§@¥Ò«¬¬y·PªºªvÀø¤Î¹w¨¾
(CDC
2006)¡C¤@¨Ç§@ªÌ§ó´£¥X´¶¹M¤£¤¹³\ª÷èÖJÓi¤Îª÷è¤AÓiªº¨Ï¥Î (Jefferson
2006)¡C
±Ä¥ÎM2§í¨î¾¯ªº¼x¥ü
¥Î¤ñ¸û¤èªkªº¬ã¨s«ü¥X¡A¦b¦P¤@¾¯¶q¤U¡A¬Û¤ñª÷èÖJÓi¡A¤H̹ïª÷è¤AÓi¦³¸û¦nªº@¤O
(Stephenson
2001)¡Cª÷èÖJÓiªº¦n³B¬O«K©y¡A¦b¤@¨Ç¼Ú¬w°ê®a¨C¤é¥u»Ý0.5¼Ú¤¸¡A¦Óª÷è¤AÓi¨C¤én5¼Ú¤¸¡A¶ø¥q¥Lºû«hn7¼Ú¤¸¡C
[¶Ç²Î]¬y·PªºªvÀø
¦b«D½ÆÂøªºÓ®×¤¤¡A¹ï¤j³¡¤À«C¤Ö¦~¤Î¦~»´¦¨¤H¯f¤H¨Ó»¡¡AªvÀø¤èªk´N¬On¦³¨¬°÷ªº¤ô¤À¤Î¦b§É¤W¥ð®§¡C¦p¦³»Ýn¡A¥i¥H¦Ò¼{¨Ï¥Î¤AñQ¬h»Ä©Îªü´µ¤ÇªL(acetylsalicyclic
acid)ªvÀø (¨C3-4¤p®É0.6-0.9§J)¡AÀYµh¡Bµo¿N¡B¦Ùµhµ¥³q±`¥i¥H¦b¼Æ¤p®É¤º¦nÂà¡CµM¦Ó¡AnÁ×§K¦b18·³©Î¥H¤Uªº¤pµ£¨¤W¨Ï¥Î¤ô·¨»ÄÆQ¡A°ò©ó¤ô·¨»ÄÆQªº¨Ï¥Î»P¹p¤óºî¦X¯gªºÃö«Y¡C¦b³o¨Ç±¡ªp¤U¡A¤AñQ®ò×ô
(acetaminophen) ©Î¥¬¬¥¤À (ibuprofen) ¬O´¶¹Mªº¥N´À«~¡C
»ó¶ë¥i¥H¨Ï¥Î¼QÃú©Îºw¾¯ªvÀø¡A¦Ó«y¹Â«h¥H¤ô»]®ð¡C¥u¦³¤@¤p³¡¥÷¯f¤H»Ýn¨Ï¥Î«y¹Â§í¨îÃÄ¡C°h¿N«á¡Aª`·Nn´`§Çº¥¶i¦a¦^´_¥¿±`¬¡°Ê¡C³o¹ï±w¦³ÄY««¬¯e¯fªº¯f¤H¨Ó»¡¯S§O«n¡C
§Ü¥Í¯ÀÀøªkÀ³¯dµ¹¦¸¥Í²Óµß©ÊªÍª¢ªºªvÀø¡C²z·Q¦a¡AÃĪ«ªº¿ï¾ÜÀ³µø¥G©I§l¹D¼Ë¥»ªº²Äõ¤ó¬V¦â¤Î°ö¾i¡CµM¦Ó¡A¦b¤é±`²ßºD¤º¡A¤£¬O®É±`¯à¨M©w¨ä¯fì¾Ç¡A¦]¦¹ªvÀø¬O¸gÅç©Êªº¡A³o¨Ç±¡ªp¤U·|¨Ï¥Î¹ï¤j³¡¤À¯fìÅ馳®Äªº§ÜµßÃĪ«
(³Ì«n¬OªÍª¢Âù²yµß©ÎªÍª¢Ãì²yµßS. pneumoniae¡Aª÷¶À¸²µå²yµßS.
aureus ¤Î¶Ý¦å±ìµßH. influenzae)¡C
¦b§óÄY«ªºÓ®×¤¤¡A¤ä´©Àøªk¥]¬A¦³²GÅé©M¹q¸Ñ½èªº±±¨î¡A¥H¤Î³Ì«á¸É¥R©Êªº®ñ®ð¡A´¡ºÞ¡A¤Î»²§U©Ê´«®ð¡C
Ãö©ó¤HÃþH5N1¬y·PªººÞ²zªº§ó¸Ô²Ó¸ê®Æ¡A½Ð¬Ý¥H¤Uªº´yz¡C
§Ü¯f¬rªvÀø
¨ü¨ì¬y·P·P¬V¡A¦Ó²£¥Í¯gª¬¤£¶W¹L¨â¤Ñªº¤@·³©Î¥H¤W¯f¤Hªº«D½ÆÂø©Ê«æ©Ê¯e¯f¶ø¥q¥Lºû¬O¾A¥Î§@ªvÀø¡C«ØÄ³ªº¶ø¥q¥LºûªvÀøÀøµ{¬°´Á¤¤é
(¦ý¦bÄY«H5N1·P¬V¥i¯à·|ªø¨Ç)¡C¦¹¥~¡A¥ç¦³³ø§i´£¥X¬°´Á¤C¤éªºµ{§Ç§@¬°¦P¤@¦~ÄÖ²Õ§O(¼Ú·ù:
≥13·³) ªº¬y·P¹w¨¾ªvÀø¡C
¨ü¨ì¬y·P·P¬V¡A¦Ó²£¥Í¯gª¬¤£¶W¹L¨â¤Ñªº¤C·³©Î¥H¤W¯f¤Hªº«D½ÆÂø©Ê«æ©Ê¯e¯f¤ã¨º¦Ì°¶¬O¾A¥Î§@ªvÀø¡C°£¤F¨âÓ°ê®a¥~¡A¤ã¨º¦Ì°¶¨S¦³±o¨ì³\¥i§@¹w¨¾¥Î³~¡CªvÀøªºÀøµ{³q±`»Ýn5¤é¡C
ª÷è¤AÓi¤Îª÷èÖJÓi¹ï¤A«¬¬y·P¯f¬r¨Ã¨S¦³®Ä¡A©Ò¥H¥u¬O³Q«ü¥Ü¥Î§@¥Ñ¥Ò«¬¬y·P¯f¬r¤Þ°_ªº¯e¯fªº¹w¨¾¤ÎªvÀø¡C¬°´î¤Ö¹ï§Ü¯f¬rÃĪ«¦³§ÜÃĩʪº¯f¬rªº¥X²{¡Aª÷èÖJÓi©Îª÷è¤AÓiªºªvÀøÀ³¦bÁ{§É¨ü«OÃÒ«á¥ß§Y¤¤¤î¡A¨å«¬¬OªvÀø«á3¦Ü5¤é«á©Î¯f¼x¤Î¯gª¬®ø¥¢«á24¦Ü48¤p®É¤§¶¡
(CDC
2005)¡C
½Ðª`·N¡A¦b¬ü°ê¡A¯e¯f¹w¨¾¤Î±±¨î¤¤¤ß«ØÄ³¡A¤£n¦b¬ü°ê2005-06¾l¤Uªº¬y·P©u¡A±Ä¥Îª÷èÖJÓi»Pª÷è¤AÓi§@¥Ò«¬¬y·PªºªvÀø©Î¹w¨¾
(CDC
2006)¡C
§Ü¯f¬r¹w¨¾
¤@¨Ç¬ã¨sÅã¥Ü¡A¯«¸gÓi»ÄžJ§í¨î¾¯¹ï¹w¨¾°·±d¦¨¤H¦bºò±K±µÄ²«áªºÁ{§É¬y·P¦³®Ä (Hayden
2000, Welliver
2001, Hayden
2004)¡C¥¦Ì¥ç¦b©uԩʹw¨¾¤¤³Q¨Ï¥Î (Monto
1999, Hayden
1999)¡C¦b©Ò¦³³o¨Ç¬ã¨s¤¤¡A¯«¸gÓi»ÄžJ§í¨î¾¯¬O70¦Ü90%¦³®Ä¹w¨¾¥Ò«¬¤Î¤A«¬¬y·P·P¬V¤Þ°_ªº¯e¯f¡C°£¤F¨âÓ°ê®a¥~¡A¶ø¥q¥Lºû¬O²{¦b°ß¤@¤@ºØÀòã³\§@¹w¨¾¥Î³~ªº¯«¸gÓi»ÄžJ§í¨î¾¯¡CY²±¦æªº«~ºØ¬O¥Ò«¬¬y·P¡A«h©Î·|¦Ò¼{¨Ï¥Îª÷èÖJÓi§@¹w¨¾¥Î³~¡C
·í¨M©w¹ï§Ü¬y·P·P¬Vªº§Ü¯f¬r¹w¨¾ªº®É¾÷©M«ùÄò®É¶¡®É¡A¤@©wn¦Ò¼{¨ä¶O¥Î¡A©Ó¿Õ¡A¥H¤Î¼ç¦b°Æ§@¥Î³o¨ÇºØºØªº¦Ò¼{¡C§@¬°¦³®Äªº©uԩʹw¨¾¡A¤@©wn¦b¾ãÓªÀ°ÏÃzµoªº´Á¶¡ªA¥ÎÃĪ«¡A¤@¯ë¶W¹L¤»¬P´Á¡C³o¤èªk©Î³\¤£¦Eºâ¡A¯S§O¬O»P¨C¦~±µºØ¤ñ¸û
(Patriarca 1989)¡C
¦b¥þ²y¬y¦æ¯e¯fªº±¡ªp¤U¡AY¤U¤@Ó¬y¦æ«~ºØ¹ïM2§í¨î¾¯¦³§ÜÃÄ©Ê (¦p2004¤Î2005¦~²±¦æ©óªF«n¨Èªº¤@¨ÇH5N1«~ºØªº¦å²M«¬)¡A¯«¸gÓi»Ä?§í¨î¾¯«ùÄòµu¯Ê¡A«h¥i¯à¥u¦³§ó¤Öªº¹w¨¾¾÷·|¡CYµo¥Í³o±¡ªp¡A¤j³¡¤À¥i¥ÎªºÃĪ«¤j·§·|¹w¯d§@ªvÀø¥Î³~¡A¦Ó¹w¨¾¤u§@©Î¥u§½©ó¦³¼ÉÅS·ÀIªº¥Ø¼Ð¸s
(¦p°·±d¤u§@ªÌ)¡C
¦b©u¸`©Ê¬y¦æ©Ê·P«_¡A¦b¥H¤U±¡ªpÀ³¸Ó¦Ò¼{¹w¨¾±¹¬I(§ï½s CDC
2005):
- ¦b¬y¦æ©Ê·P«_¬¡°Ê¤w¶}©l«á, ³Q±µºØªº°ª·ÀI¤H¤ó
·í¬y¦æ©Ê·P«_¬Ì]³Q°õ¦æ¤Î¬y¦æ©Ê·P«_¯f¬r¬y³q®É¡AÀ³¸Ó¦Ò¼{¦b³Qµø¬°°ª·ÀIªº¤H¶i¦æ¨âÓ¬P´Áªº¤Æ¾Ç¹w¨¾ªvÀø¡C¤Ö©ó¤E·³º¦¸±µ¨ü¬y¦æ©Ê·P«_¬Ì]ªº«Äµ£¡A¥i¯à»Ýn¤»Ó¬P´Áªº¹w¨¾(§Y¦b²Ä¤@¾¯¶q¬Ì]¨Ï¥Î«á,
¥|Ó¬P´Áªº¹w¨¾¤Î¦b²Ä¤G¾¯¶q¬Ì]¨Ï¥Î«á, ÃB¥~¨âÓ¬P´Áªº¹w¨¾¡C
- ´£¨Ñ·ÓÅU°ª·ÀI¤H¤óªºÂåÅ@¤Hû
ÂåÀø«O°·¤Hû¡A¦pªG³Q¬y¦æ©Ê·P«_¯f¬r¶Ç¬V¡A¯à¶Ç¼½¯e¯f¡C¦b¬y¦æ©Ê·P«_¬¡°Ê®p³»´Á¶¡¡A¥i¦Ò¼{¥H§Ü¯f¬rÃĪ«¹w¨¾ªvÀøµ¹»P°ª·ÀIªº¤H¤Î»P°ª·ÀI¤H¤ó¦³ÀWÁc±µÄ²¦Ó¥¼ª`®g¹L¬Ì]ªº¤H±Ä¥Î¡C¦³ÀWÁc±µÄ²ªº¤H¥]¬AÂå°|¡B¶E©Ò©MºC©Ê·ÓÅU³]¬Iªºû¤u¡B®a®x¦¨û¡B¤WªùªA°ÈÅ@¤h©M§ÓÄ@¤u§@ªÌ¡C
¦pªGÃzµo¬O¥Ñ¬Ì]¤]³\¤]¤£¯à±±¨îªº¬y¦æ©Ê·P«_ªº¤£¦P«~ºØ³y¦¨¡A¤£ºÞ¥L̪º±µºØª¬ºA¦p¦ó¡AÀ³¸Ó¬°©Ò¦³³o¤@Ãþ¤H¶i¦æ¤Æ¾Ç¹w¨¾ªvÀøªk¡C
- ¯Ê¥F§K¬Ì¤Oªº¤H
¤Æ¾Ç¹w¨¾ªk¥i¦Ò¼{¥Î©ó°ª·ÀI¤Î¹wp¹ï¬y¦æ©Ê·P«_¬Ì]¦³¤£¨¬°÷ªº§ÜÅé¤ÏÀ³ªº¤H¡C³oÓÃþ§O¥]¬A·P¬V·R´þ¯fHIVªº¤H¡A¥Dn¬°¨º¨Ç·P¬V°ª¯Åªº·R´þ¯fHIVªº¤H¡C
- ¨ä¥L¤H
¤Æ¾Ç¹w¨¾ªvÀøªk¦b¾ãÓ¬y¦æ©Ê·P«_©u¸`©Î¦b¬y¦æ©Ê·P«_¬¡°Ê°ª®p³B¬I©ó°ª·ÀI¦Ó¤£À³¸Ó³Q±µºØªº¤H¡A¤]³\¬O¾A·íªº¡C
- ¦w¸m³B©ó°ª·ÀIªº¤Hªº°|ªÀ¤Î¾÷ºc
¦b¬y¦æ©Ê·P«_¬¡°Ê³Qµo²{«á¡A¦³ÃÒ¾ÚÅã¥Ü¡AºÉ³t¹ê¦æ¦Ñ¤H°|¤º¾÷ºc½d³òªº¹w¨¾±¹¬I¡A¤]³\¬O¹ï±±¨î¾÷ºcÃzµo¬y·Pªº¬Ã¶Qµ¦²¤
(Peters 2001, Bowles 2002, Monto 2004) ·íÃÒ¹ê©Î®ÉÃhºÃ¬y¦æ©Ê·P«_Ãzµoµo¥Í®É¡A¤£ºÞ¥L̬O§_¦b¦«eÃzµo¤¤±µ¨ü¤F¬y¦æ©Ê·P«_±µºØ¡A¤Æ¾Ç¹w¨¾ªvÀøªkÀ³¸Ó¦b³Ì¤Ö¨âÓ¬P´Á¾¨¦¹ï©Ò¦³©~¥Á°õ¦æ¡C
¦pªGºÊ¹îÅã¥Ü·s®×¥óÄ~Äòµo¥Í¡A¤Æ¾Ç¹w¨¾ªvÀøªkÀ³¸ÓÄ~Äòª½¨ìÃzµoµ²§À«á¤j¬ù¤@Ó¬P´Á¡C ¨C¤@©~¥Áªº¾¯¶qÀ³¸Ó¿W¥ß³B²z¡C
¤Æ¾Ç¹w¨¾ªvÀøªk¤]¥i¦V³B©ó°ª·ÀI·ÓÅU¤H¦Ó¥¼ª`®g¹L¬Ì]ªºÂ¾û´£¨Ñ¡C¦pªGÃzµo¬O¥Ñ»P¬Ì]¤£¤Ó¬Û°tªº¬y¦æ©Ê·P«_ªº¤£¦P«~ºØ³y¦¨¡A¤£ºÞ¥L̪º±µºØª¬ºA¡A©Ò¦³¶±û¤]À³§@¥X¹w¨¾ªvÀø¡C
¯S§O±¡ªp
«Ä¤l
¶ø´µ¥L°¶(Oseltamivir) ¡G 1¦Ü12·³ªº«Ä¤l²M°£¬¡ÅD¥NÁª«¶ø´µ¥L°¶ßn¤Æª«¤ñ¤j«Ä¤l©M¦¨¤H§ó§Ö¡A³y¦¨§ó§CªºÃĪ«±µÄ²¡C
»P¼Ð·Ç¥Î©ó¦¨¤H¨C¤é¨â¦¸1 mg/kgÃĶq¤ñ¸û, ¼W¥[¾¯¶q¨ì¨C¤é¨â¦¸¨C¦¸2 mg/kg¾ÉP¬Û¹ïµ¥ªºÃĪ«±µÄ²
(Oo
2001)¡C 1·³ªºÀ¦¨à ¯à°ª®Ä²v¦a¶i¦æ¥NÁ©M±Æªn¶ø´µ¥L°¶(Oo 2003)¡A¦ý©ó¥®¨à¨¤W¥Î¶ø´µ¥L°¶¬O¸T§Ò(FDA
2005). ¤ã¨º¦Ì°¶¡]zanamivir¡^¡G ¦b¼Ú¬w¦@Åé¡A¤ã¨º¦Ì°¶³Q§åã¥Î©ó12·³©Î¥H¤Wªº«Ä¤l(¬ü°ê¡G
7·³)¡C
ª÷èÓi(Amantadine)¡Aª÷è¤AÓi(rimantadine)¡G ¦]¬Û¹ï¦a§C®Ä¤O©M¹ï¹¹D©M¤¤¼Ï¯«¸g¨t²ÎCNS¦³°ª·ÀIªº¤£§Q¼vÅT¡A§@ªÌ¤£±À¤¶©ó«Ä¤l¨¤W¥Îª÷èÓi©Îª÷è¤AÓi¡C
³Q«d®zªºµÇŦ§@¥Î
¶ø´µ¥L°¶ ¡G ²×ºÝ¦å¼ß±Æ°£¥b°I´Á¦b°·±d¦¨¤H¬O1.8 h¡C ¦b¦³µÇŦ·l¶Ëªº¯f¤H¤W¡A¥NÁª«²M°£»P¦Ù®ò»ÄÓþ(creatinine)²M°£ª½½u©Ê¦a´î¤Ö,
©M¦bÓ§O¤H¤ó¤fªA¥H«á¡A¦Ù®ò»ÄÓþ²M°£¤Ö©ó¨C¤ÀÄÁ30²@¤É < 30 ml/min¥§¡¥b°I´Á¬O23
h (Doucette 2001)¡C ¦Ù®ò»ÄÓþ²M°£ < 30 ml/min(1.8 l/h)ªº¯f¤H,
¨C¤é¤@¦¸¾¯¶q´î¤Ö¦Ü75²@§J¬O³Q±À¤¶ªº(He 1999); ¦b¹w¨¾¤è±¡A ¹j¤Ñ75²@§J¾¯¶q¬O³Q±À¤¶ªº¡C¹ï©ó¦å²G³zªRªvÀøªº±wªÌ,
¨S¦³ªvÀø©Î¹w¨¾ÃĶqªº±À¤¶¬O¥i¤Þ¥Îªº¡C
¤ã¨º¦Ì°¶ ¡G¦bµÇŦ§@¥Î¦³»´·L¦Ü¤¤«×©ÎÄY«·l¶Ëªº±wªÌ, ¦b5¤ÑªºªvÀø¹Lµ{´Á¶¡, »s³yªÌ«ÅºÙ¨S¦³¹ïÃĶqªº½Õ¾ã¬O»Ýn
(Relenza)¡C
ª÷è¤AÓi ¡G µÇ¥\¯à¤£¥þ¾ÉPª÷è¤AÓi¥NÁª«¦b¦å¼ß¤¤ªº¿@«×¼W¥[¡C¦å²G³zªR¤£¯à¥h°£ª÷è¤AÓi¡C¦Ù®ò»ÄÓþ²M°£<
10 ml/minªº¯f¤H, ¨C¤é¾¯¶q´î¤Ö¦Ü100²@§J¬O³Q±À¤¶ªº¡C¦b³zªRªº¤é¤l¨S¦³»Ýn¸É¥RÃĶq(Capparelli
1988)¡CµÇ¥\¯à»´·L¤£¥þ©M¦~¦Ñªº±wªÌ¡A¥Îª÷è¤AÓi«á, ¤£§Q¼vÅTÀ³¸Ó³QºÊ´ú¡C
ª÷èÓi¡GÓ§O¦~¬ö¤j©ó¤»¤Q·³©M¦Ù®ò»ÄÓþ²M°£§C©ó¨C¤ÀÄÁ¥|¤Q²@¤É(< 40 ml/min),ÃĶq´î¤Ö¬O³Q±À¤¶ªº¡Cª÷èÓi¾¯¶q«ü«n,
®Ú¾Ú¦Ù®ò»ÄÓþ²M°£, ¬O¦ì©ó¥]¸Ë´¡¤Jª«¡C ±wªÌÀ³¸Ó³Q¥J²Ó¦a¯d·N¦³®`¤ÏÀ³¡C¦b³o¨Ç±¡ªp¤U¡A¦Ò¼{¶i¤@¨B´î¤ÖÃĶq©Î°±ªAÃĪ«¡C¦å²G³zªR¬O¤£·|¥h°£ª÷èÓiªº¡C
³Q«d®zªº¨x¥\¯à
¶ø´µ¥L°¶ ¡G ±wªÌªº¶ø´µ¥L°¶·s³¯¥NÁ¨S¦³¦b¤¤«×¨x«d®zªº¯f¤H¤¤³Q§´¨ó¡A¤ÎÃĶq½Õ¾ã¹ï³o¨Ç±wªÌ¬O¨S¦³»Ýnªº(Snell
2005)¡C¤ã¨º¦Ì°¶ ¡G¦b¤Hªº¨x©xªº±¡ªp¤U¤£¨}¤´¥¼³Q¬ã¨s¡C
ª÷è¤AÓi ¡G ¦b¤HªºÄY«¨x©x¤£¨}±¡ªp¤U¡A ª÷è¤AÓiªºÃĶq´î¤Ö¬O³Q±À¤¶ªº¡C
ª÷èÓi¡G«Ü¤ÖÆ[¹î¨ìª÷èÓi¹ï©ó¨xŦ¯fªº±wªÌµo¥Í¦³®`¤ÏÀ³¡C
µjÅ˯e¯f(Seizure Disorders)
´¿¦³µjÅ˯e¯f¦Ó¨S¦³±µ¨üÂíµj¾¯Àøµ{¦ýªA¥Îª÷èÓi©Î?è¤AÓiªº±wªÌ¤¤ , µjÅ˯e¯f(©Î¹³µjÅ˪º¬¡°Ê)«Ü¤Ö³Q°Oz¡C
Ãh¥¥
¦pªG¼ç¦b¦n³B©è®ø¹ïL¨à¼ç¦bªº·ÀI (Ãh¥¥Ãþ§OC) ¡A¥H¤W´£¨ìªº©Ò¦³ÃĪ«¤~¥i¦bÃh¥¥´Á¶¡¨Ï¥Î¡C
¤HÃþH5N1¬y¦æ©Ê·P«_ªvÀø
ªvÀø¤HÃþH5N1¯e¯fªº¸gÅç¬O¦³ªº¡Ðª½¦Ü2006¦~3¤ë8¤é¬°¤î¡A¤w¦³175 ÃÒ¹êӮפw¦V¥@¬É½Ã¥Í²Õ´(WHO)³ø§i(WHO
2006), ©M¨´¤µ¥Xª©ªºÁ{§É³ø§i¥u¥]¬A´X¦W±wªÌ(Yuen
1998, Chan
2002, Hien
2004, Chotpitayasunondh
2005, WHO
2005, de
Jong 2005)¡C
®Ú¾Ú·í«e¼Æ¾Ú¡A·í«e¬y³qªºH5N1«~ºØ§Î¦¨ªº¬y¦æ©Ê·P«_¯e¯fªvÀø¡A¥i¯à»P "¨å«¬" ¬y¦æ©Ê·P«_ªvÀø¦³¨Ç¤£¦P
(WHO 2006b). µM¦Ó¡Aȱoª`·Nªº¬O¡A·í«eªº«ØÄ³¬Oªì¨Bªº¡A¨Ã¥B¦p¦³·s¼Æ¾Ú, ×§ï¬O¥i¯àªº¡G
- ¦³ÃhºÃªºH5N1¬y¦æ©Ê·P«_¯f¤H, ¦bµ¥«Ý¹êÅç«Ç¸ÕÅ窺µ²ªG´Á¶¡, À³¸ÓºÉ¦±µ¨ü¯«¸g®ò»Ä
§Ü¤Æ¾¯(WHO
2005)¡C
- ¶ø´µ¥L°¶(Tamiflu®)³Q»{¬°¬O·í«e©ÒÀ³¿ï¾ÜªºÃĪ«¡C
- ¦Ò¼{¦bÄY«¯e¯f¤¤, ¼W¥[¶ø´µ¥L°¶ªº¾¯¶q (¦¨¤H¨C¤é¨â¦¸¨C¦¸150²@§J )©MÄ~Äò§@§óªøªºªvÀø(7
¦Ü10¤Ñ©Î§óªø) (WHO
2005)¡C
- ¯f¬r ©è§Ü¥i¯àµo¥Í©M¦bÁ{§É´c¤Æ¤§«eµo¥Í(de
Jong 2005)¡C
- §Y¨Ï¦b¥X²{¯gª¬8¤Ñ«á°_©l,¥H¶ø´µ¥L°¶ªvÀø¥i¯à¬O¦³§Qªº¡A¦pªG¦³«ùÄòªº¯f¬r½Æ»sªºÃÒ¾Ú
(WHO
2005, de
Jong 2005)¡C
Ãþ¥Ö½è¿E¯À¤vÀW±K¦a³Q¨Ï¥Î¡A¦ý¦³¥Ù¬Þµ²ªG¡C¦b¤@²Õ¤¤¡A¤C¦W±wªÌ¦³¤»¦W¡A ¥HÃþ¥Ö½è¿E¯À§@ªvÀø¡A¤w¦º¤F(Hien
2004)¡C¤T´áÐü®Ö (Ribavirin)¡B¤zÂZ¯Àªüº¸ªk(interferon
alpha)¤Î¨ä¥L§K¬Ì½Õ¸`ÃĪ«¤w©Ò¦³³Q¨Ï¥Î¡A ¦ý¨S¦³¥i«Hªºµ²ªG¡C
¦bÄY«ªº±¡ªp¤U¡A ³q·¤ä«ù©M¯S§OÅ@²z¥i¯à¬O¤J°|ªº¼Æ¤Ñ¤º«K»Ýnªº (Hien
2004, Chotpitayasunondh
2005).
¶Ç¬V©Ê¹w¨¾
·íÃhºÃ¦³¤HÃþ·P¬VH5N1®É¡A¶·±Ä¨ú¹w¨¾±¹¬I, ¨ÏÂå°|ªº´²¼½´î¦Ü³Ì¤Ö¡C ¦pªG¶EÂ_³QÃÒ¹ê¡A¸ñ¶H¯f¯gªº¥i¯àªº±µÄ²ªÌ¥²¶·³Q½T©w¥H«P¶i§Ü¯f¬rÀøªkªº¦´Á¤z¹w¡A¬°¤F´î¤Öµo¯f²v©M¦º¤`²v¤Î¶i¤@¨B¨î¯e¯fªº¶Ç¼½
(WHO2004)¡C
¤@¯ë¶Ç¬VºÞ²zªº±¹¬I
¦bÂå°|À³¸ÓÃöª`ªº©Ò¦³±wªÌªº¶Ç¬VºÞ²z±¹¬I, ¥]¬A¼Ð·Ç¨¾³Æ±¹¬I(Garner
1996)¡C ¦pªG¬y¦æ©Ê·P«_H5N1¶Ç¬Vªº¶EÂ_³Q¦Ò¼{¬°Á{§É¯SÂIªº®Ú¾Ú¡AÃB¥~ªº¨¾³Æ±¹¬IÀ³¸Ó¹ê¬I¡Aª½¦Ü¶EÂ_¥i³Q±Æ°£¬°¤î¡C
¯S§O¶Ç¬VºÞ²z±¹¬I
¬y¦æ©Ê·P«_¯f¬r¬O¥Ñ¤pºw©M¸ªj®Ö©Ò¶Ç°e(¦bªÅ®ð¤¤)¡C ¥t¥~¡Aª½±µ©M¶¡±µ¶Ç¬V©Ê±µÄ²¤]¬O¦³¥i¯àªº¡CÁöµM·í«e¨S¦³ÃÒ¾ÚÅã¥Ü¦b¤H¤§¤¤H5N1¯f¬r¬O³Q¶Ç°e¡A¥@¬É½Ã¥Í²Õ´«ØÄ³¥H¤U¨¾³Æ±¹¬I(WHO
2004) ¡G
- °£¸ªj©M±µÄ²¨¾³Æ±¹¬I¤§¥~, ±Ä¥Î°ª¦¨®Ä¤f¸n¡C
- ±wªÌÀ³³Q¦w¸m¦btÀ£©Ð¡C
- ±wªÌÀ³¹jÂ÷¨ì³æ¤H©Ð¡C ¦pªG¤£¯à¥Î³æ¤H©Ð¡A¤À¶}¤@¶¤±wªÌ¦b¿ï©wªº¦h§É©Ð¶¡©Î¯f°Ï¡C
- ¯f¤Hªº§É¶ZÂ÷À³¸Ó¶W¹L1¦Ì©M¥i¥Îª«²z»Ùê¤À¹j (§Y±c¹õ¡B¹jªO)¡C
¬°«OÅ@ÂåÅ@¤Hû(HCWs)©M¨ä¥LÂå°|¤Hû¡A¥²¶·¿í·Ó¥H¤U«ØÄ³(WHO2004)
¡G
- HCWs À³±a¤@Ó°ª¦¨®Ä¤f¸n (¼Ú¬wCE§å㪺¤H¤u©I§l¾÷©Î¬ü°êNIOSH«OÃÒªºN-95)¡A»o¤l¡B±¾×ªO©ÎÅ@¥ØÃè¡B¤Î¤â®M«OÅ@¦Û¤v¡C
¹ï ³Ìªñ¤wÄÄ©ú, ¦b¥þ°ê¬y¦æ©Ê³]¸m¤W, ÂåÅ@¤Hû¹ï±¨ãªº¥Î³~ (WHO2005b)¡C·í®É±`¨Ï¥Î¤â³N¤f¸n¡A¥i´î¤Ö¶Ç¬Vªº·ÀI¡A¦ý¨Ã¤£ÅãµÛ¦a´î¤Ö(Loeb
2004)¡C
- ¨î»P±wªÌ¦³ª½±µÁpôªºHCWsªº¼Æ¦r; ³o¨ÇHCWs¤£À³¸Ó·ÓÅU¨ä¥L±wªÌ¡C
- ¥i±µªñ³o¨Ç±wªÌÀô¹Òªº¨ä¥LÂå°|¶±û(§Y²M¼ä¤u¡A¹êÅç«Ç¤Hû)¤§¼Æ¶q, ¤]À³¸Ó¨î¡C
- ¦b¶Ç¬V±±¨î¨¾³Æ±¹¬I¤W, ¿ï©wªº©Ò¦³HCWsÀ³¨ü¨ì¾A·í°V½m¡C¨î¨Ó³Xªº¹C«È¼Æ¦r¤Î´£¨Ñ¾A·íÓ¤H¨¾Å@°t³Æµ¹¥LÌ©M«ü¥Ü¥L̦p¦ó¨Ï¥Î¡C
- ½Ð¨D»P¯f¤H¦³ª½±µ±µÄ²ªºHCWs¨C¤é¨â¦¸ºÊ´ú¥L̦ۤvªºÅé·Å©M¦VÂå°|·í§½³ø§i¥ô¦óµo¼ö¨Æ¥ó¡C
µo¿N°ª©óÄá¤ó38«×(> 38«×)©M»P¯f¤H¦³ª½±µ±µÄ²ªºHCWs¡AÀ³¥ß§Yªv²z¡C
- ¹ï¥K¦ó¦³¼ç¦b»P±wªÌ¸ªj¦³±µÄ²¦Ó¨S¦³¨¬°÷Ó¤H¨¾Å@¸Ë³ÆªºHCW, À³´£¨Ñ¼ÉÅS©Ê«á(post-exposure)ªº¹w¨¾µ¹¥LÌ
(¨Ò¦p¡A³sÄò7¤Ñ¨C¤é¤fªA75²@§J¶ø´µ¥L°¶) ¡C
- ¤£¾AªºHCWs¬O¤£À³¸Óª½±µÅ@²z¯f¤Hªº¡A¦]¬°¥LÌÅé®z¡A¦Ó¥B·í¼ÉÅS©ó¬y¦æ©Ê·P«_A (H5N1)¯f¬r®É,
§ó¥i¯à§Î¦¨ÄY«¯f¯g¡C
- ¾A·í¦a¦w¸m¼oª«¦b±K«Ê, ¤£º¯³z©Ê, ¤Î¦³²M·¡¼Ð°O¬°"¥Í¤Æ¦M®`" ªº³U¤l¤Î«áÀ³µI¤Æ¡C¸g±wªÌ±µÄ²ªº¨È³Â¥¬©M¥i¦A¥Îªº§÷®ÆÀ³¸Ó¤À¶}¦a³B²z¤Î®ø¬r¡C
±µÄ²°l¬d
¿ë»{±µÄ²ªÌ¤Î¿ë»{¨º¨Ç¥i¯à¤w³Q¼ÉÅS©ó¦@¦P·P¬V·½ÀYªº¤H¡C
±µÄ²ªÌªº©w¸q¬O¨º¨Ç¤w»P½T¶E¤F±w¨ä¬y¦æ©Ê·P«_A(H5N1)ªº¤H, ¦P®É¥L¤]¦b¨ä·P¬V´Á¶¡(§Y,
¦b¯gª¬°_©l¤§«eªº¤@¤Ñ¨ì¦b¯gª¬«áªº²Ä¤C¤Ñ¡A©Î¥Ñ¥þ°ê¤½¦@½Ã¥Í·í§½³W©wªº¤é´Á¡A©Îªí©ú¦b "ÄÀ©ñ¬Fµ¦"
³¡¤Àªº¤é´Á) ¤À¨É¦P¤@©ú½T¦a¤èªº¤H (®a®x¡B¤j®a®x¡BÂå°|©Î¨ä¥L¦í¦v¾÷ºc¡Ax¨ÆÀç©Ð©Î®ø»ºÀç¦a)
(WHO2004)¡C³o¨Ç¤HÀ³¸Ó¦b¹ï³Q²o³sªº±wªÌ©Î¦@·½ÀY,
¦b³Ì«á¼ÉÅS«á³sÄò¤C¤Ñ¡A³QºÊ´ú¡A©Mn¨D¥L̨C¤éÀˬdÅé·Å¨â¦¸¡C¦pªG³QºÊ´úªº¤Hµo¿N(> 38«×)¡A¤Î«y¹Â©Î®ð«P,
À³¸Ó¥ß¨è¶Eªv(WHO2004)¡C
ÄÀ©ñ¬Fµ¦
¥@¬É½Ã¥Í²Õ´«ØÄ³¦bµo¿N°h¤F«áªº7¤Ñ¡A¬°¦¨¤H±wªÌ³]pªº¶Ç¬V±±¨î¨¾³Æ±¹¬IÀ³¤´µM¥Í®Ä¡C¦´Á¤HÃþ¬y¦æ©Ê·P«_¬ã¨sªí©ú,
¤Ö©ó¤Q¤G·³ªº¤p«Ä¯à¦bµo¯f«á¤G¤Q¤@¤Ñ¤º¨ÌµM´²µo¯f¬r¡C©Ò¥H²z·Q¦a¡A¬°¤p«Äªº¶Ç¬VºÞ²z±¹¬IÀ³¦b³o´Á¶¡ºû«ù
(WHO2004)¡C
¦p¥H¤W±¹¬I¬O¤£¥i¦æªº(¥Ñ©ó¯Ê¥F¦a¤è¸ê·½)¡A®a®xÀ³¸Ó¦bÓ¤H½Ã¥Í©M¶Ç¬VºÞ²z±¹¬I¤W³Q±Ð¨| (§Y¬~¤â¤Î¦p«Ä¤l¤´µM«y¹Âªº¸Ü,
¥Î¯È©Î¤â³N¤f¸n¡C) «Ä¤l¤£À³¸Ó¦b³o¬q´Á¶¡¦^¾Ç®Õ(WHO2004)¡C
¥þ²y©Ê¬y¦æ¯f¹w¨¾
¦³¤@¨ÇÃÒ¾Ú«ü¡A¦b·½ÀY¥H§Ü¯f¬r¹w¨¾©MªÀ·|¶ZÂ÷±¹¬I¬°²Õ¦X¬O¥i¯à«ÊÂê©M°£¥h¬ð²{ªº¥þ°ê¬y¦æ©Ê·P«_«~ºØªº(Ferguson
2005)¡C§@ªÌ¹B¥Î¤F¤@Ó¦bªF«n¨È¬y¦æ©Ê·P«_¶Ç¼½ªº¼Ò¥é¼Ò«¬¥hµû¦ô®w¦s¤j¶q§Ü¯f¬rÃĪ«¡A§@¬°¹w¨¾¯e¯f¥Î³~ªº¥Ø¼Ð¡A¹w´ú¤T¦Ê¸U§Ü¯f¬rÃĪ«ªº®w¦s¶qÀ³¸Ó¬O¥R¨¬ªº¡C
¥@¬É½Ã¥Í²Õ´³Ìªñ¶}©l«Ø¥ß§Ü¯f¬rÃĪ«°ê»Ú®w¦s, ±N³Q¬£µo¨ì´é²{ªº¬y¦æ©Ê·P«_¥þ°ê¬y¦æ¯e¯f°Ï°ì(WHO20000824)¡C
¦pªG¬y¦æ¯f¤£¯à¥]§t¨ä·½ÀY¡A¨³³t¤z¹w¦Ü¤Ö¥i©µ¿ð°ê»Ú¶Ç¼½©MÀò¨ú¬Ã¶Qªº®É¶¡¡C n³oµ¦²¤¹B§@¡A¤@©w¼Æ¶qªºÃöÁä±ø¥ó¥²¶·²Å¦X¥H¹F¨ì°ª¥i¯à©Êªº¦¨¥\(Ferguson
2005) ¡G
- 쥻ªº®×¥ó¸sªº¨³³tŲ©w¡A
- ¹ï¥Ø¼Ð¸sªvÀøªº¨³³t¡A±Ó·P®×¥ó°»¬d©M¥I¥æ¡A³Ì¦n¦b¥X²{®×¥ó¤§¥|¤Q¤K¤p®É¤§¤º¡A
- ¦³®ÄªºªvÀø¸û°ª¤ñ¨Òªº¥Ø¼Ð¤H¤f¡A³Ì¦n>90%¡A
- ¨¬°÷ÃĪ«ªº®w¦s¡A³Ì¦n¦b¤T¦Ê¸U©Î§ó¦h¶ø´µ¥L°¶°µªk (¥@¬É½Ã¥Í²Õ´·í«e°t¸m³o®w¦s)¡A
- ¤H¤f¦X§@»P¹K¨î¬Fµ¦¤Î¡A ¤×¨ä¬O¡A ³Q¤Þ¤Jªº¥ô¦ó¤@ÓªÀ·|¶ZÂ÷±¹¬I¡A
- ¦b¬Fµ¦µo®i¤Wªº°ê»Ú¦X§@¡A¬y¦æ¯fºÊµ¦©M±±¨îµ¦²¤±¹¬I¡C
ȱoª`·Nªº¬O¡A¥Ñ¨ä¨Ó·½°±¤î¥þ°ê¬y¦æ¯f©Î©µ¿ð¨ä°ê»Ú¶Ç¼½ªº·Qªk¡A¬O¤@ºØ«Ü§l¤Þ¡A¦ý¬O±q¥¼¸gÃҹꪺ°²»¡¡C
¨ì¥Ø«e¬°¤î¡A¤@¥¹¥¦¦b¤H¤f¤¤´é²{, ¥¼´¿¹Á¸Õ¦¨¥\¦a§ïÅÜ¥þ°ê¬y¦æ¯fªº¦ÛµM¸ô½u¡C ¥æ¥IÃĪ«®É¡A¹ïÃe¤j¤H¤fªºª«¬y°ÝÃD,
¬Oȱo¦Ò¼{ªº¡C¥t¥~¡A²Ä¤@¬y¦æ¯f¯f¬r«~ºØ¤£À³¸Ó¬O¨ã°ª«×¶Ç¬V©Êªº¡A¤Î¯f¬rÀ³¸Ó¨î¨ì«Ü¤pªº¦a²z±¿n¤º¡C¦³³\¦h¡m
¦pªG ¡n ¤Îµ²ªG´X¥G¬O½T©wªº¡C
µM¦Ó¡A¬y¦æ©Ê·P«_¬y¦æ¯fªº¼ç¦b¨aÃø©Ê«áªG¡A¬°¨³³t©M¦´Á¤z¹w¡A ¥@¬É½Ã¥Í²Õ´Àx³Æ§Ü¯f¬rÃĪ«ªº¾Ô²¤¬O¦b³\¦h¥þ²y¬y¦æ©Ê·Ç³Æp¹º¤¤ªº¨ä¤¤¤@ӬöQ³¡¤À¡C
µ²½×
¬°¤F´£°ª¤HÃþ¬y¦æ©Ê·P«_¶Ç¬V®Ä²vªº±±¨î, ¯«¸gÓi»Ä?»Ã¯À§Ü¤Æ¾¯ªº¤¶²Ð¬O«nªº¶¥¬q¡C ¤µ¤Ñ¡A¯«¸gÓi»ÄžJ»Ã¯À§Ü¤Æ¾¯¬O°ß¤@¦³®Ä¦a¦b¤HÃþ¨¤W¹ï§Ü³Ìªñ³Q¹jÂ÷ªº°ª«×P¯f©Ê³¾Ãþ¬y¦æ©Ê·P«_¯f¬rªºÃĪ«¡C
µM¦Ó¡AÃö©óH5N1°ª«×§ÜÃĩʫ~ºØªº³ø§i±j½Õ¨Ò¦p¨ä¥L·P¬V¯f¬r, ¤HÃþ§K¬Ì¯Ê¥F¯f¬r(HIV),
§ÚÌ´¿¸g¾úªº¸gÅç¡G§Ú̱q¥¼¦³¨¬°÷ªºÃĪ«ªvÀø§Ú̪º±wªÌ¡A¤Î§ÚÌÁ`»Ýn·s©M§ó¦nªºÃĪ«¡C¦b§Ṳ́§«e¦³«¤jªº§V¤O¥h¶}µo§ó¦hÃĪ«,
¬Æ©Î¦Ü¤£·|¨C¦~§ïÅÜ, ¥]¬A©Ò¦³§Üì¤W¨È«¬¤Î¥þ¥@¬É¤H¤f³£¥i±o¨ìªº¶W¯Å¬Ì] (Osterholm
2005)¡C ³o¨Ç§V¤O±N·|¬O©ù¶Qªº¡A¦ý¥u¬O¦bª÷¿ú¤W¡G¤°»ò³£¤£¯à»P¤U¤@¦¸¥þ°ê¬y¦æªº¬y¦æ©Ê·P«_¤¤¤§³à¥¢¥Í©R§@¤ñ¸û¡C
|